Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood

NCT04147975 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2019-11-01

No results posted yet for this study

Summary

The purpose of this study is to assess the effectiveness of RaPID/BSI by testing its performance compared to blood cultures collected prospectively from consented subjects.

Conditions

  • Bacteremia
  • Candidemia

Interventions

DIAGNOSTIC_TEST

RaPID/BSI Test

RaPID/BSI Test

Sponsors & Collaborators

  • HelixBind, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-09-30
Completion
2020-10-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04147975 on ClinicalTrials.gov